openPR Logo
Press release

Product Overview And Scope Of Diffuse Large B-Cell Lymphoma Market For 2017 - 2025

05-02-2017 07:20 AM CET | Health & Medicine

Press release from: TMR Research

Product Overview And Scope Of Diffuse Large B-Cell Lymphoma Market For 2017 - 2025

Diffuse Large B-Cell Lymphoma Market: Overview

With a noticeable rise in the prevalence of diffuse large B-cell lymphoma (DLBCL), the market for DLBCL market is witnessing strong growth across the world. Analysts expect the trend to remain so over the next few years, owing to the increasing number of elderly people, the most prone to DLBCL segment of the overall population.

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non hodgkin lymphoma (NHL) and is the main reason behind more than 30% of the newly diagnosed cancer cases in the U.S. alone. The prevalence of this disease is increasing at an alarming rate, which is likely to fuel the demand for DLBCL treatments substantially in the near future, leading to a considerable market growth.

This research report offers a detailed evaluation of the global market for DLBCL on the basis of its current and historical performance. The prominent trends, growth drivers, challenges, opportunities, and the future prospects of this market have also been examined thoroughly while conducting this study. The main objective of this study is to assist the market participants in gaining a clear and deep insight into this market.

Request a Brochure of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=494

Diffuse Large B-Cell Lymphoma Market: Trends and Opportunities

The increasing incidence of DLBCL has fueled the demand for efficient therapies for its treatment across the world. With the ever-rising global geriatric population, the scenario is likely to remain more or less similar over the forthcoming years. In addition, the presence of a robust last stage pipeline of drugs ready for clinical trials and the increasing expenditure on healthcare are expected to boost this market tremendously in the years to come.

At present, the most efficient treatment for DLBCL available across the world is combination therapy that includes chemotherapy and monoclonal antibody-based drug Rituxan (rituximab). However, the development of other drugs is also taking place at a swift pace, with many of them being in various late-stage clinical trials. Alisertib (MLN8237), Bortezomib (Velcade), Brentuximab vedotin (Adcetris), Everolimus (Afinitor), Lenalidomide (Revlimid), Panobinostat, and Vorinostat (Zolinza) are some of the key pipelined projects, approval of which will gain advantages for this market in the forthcoming years.

Request for TOC of the Report @ www.tmrresearch.com/sample/sample?flag=T&rep_id=494

Diffuse Large B-Cell Lymphoma Market: Geographical Analysis

North America, followed by Europe, has surfaced as the leading contributor to the global market for DLBCL, thanks to the high prevalence of DLBCL, rising awareness level of people, and their increased disposable income. However, Asia Pacific is likely to emerge as the most promising regional market in the coming years. The strengthening economy and the improving healthcare infrastructure in this region are expected to act as the key driving force behind the growth of the Asia Pacific DLBCL market.

Diffuse Large B-Cell Lymphoma Market: Companies Mentioned in the Report

Some of the major players operating in this market are Amgen, Inc., AstraZeneca plc, Astellas Pharma, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Gilead Sciences, Inc., Genentech, Inc., Infinity Pharmaceuticals, Inc., MedImmune, LLC, Merck & Co., Inc., Novartis AG and Sanofi.

Read Complete Report @ www.tmrresearch.com/diffuse-large-b-cell-lymphoma-market

About TMR Research

TMR Research is a premier provider of customized market research and consulting ser-vices to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

Rohit Bhisey
Head - Internet Marketing
Tel: +1-415-520-1050
Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Product Overview And Scope Of Diffuse Large B-Cell Lymphoma Market For 2017 - 2025 here

News-ID: 518664 • Views: 344

More Releases from TMR Research

Software-Defined Storage Market 2025 | IBM, HPE, Fujitsu, EMC Corporation
Global Software-Defined Storage Market: Snapshot The global software-defined storage market is foreseen to roof a high intensity competitive landscape on account of a number of companies entering the scene due to the interrelation of technologies such as virtualization and cloud computing. Although the level of competition could be on a higher side, it is expected of several companies to lose their grip on the market due to reduced revenues and low
Edge Analytics Market 2017-2025 | Prism Tech, Analytic Edge, CGI Group Inc., Fog …
Global Edge Analytics Market: Snapshot The global edge analytics market has risen to the fore in recent years as a consequence of the rising importance of big data analytics in corporate operations. Rising use of machine systems utilizing Internet of Things technology is also likely to be vital for the global edge analytics market in the coming years. Rising use of data accrued from disparate systems in industrial operations and corporate
Drone-powered Business Solutions Market 2017-2025 | 3D Robotics, Phoenix Drone S …
Global Drone-powered Business Solutions Market: Snapshot Organizations worldwide are acknowledging the benefits they have derived by integrating drones in various verticals such as infrastructure maintenance, security and surveillance, inspection, mapping and surveying, and large-scale capital projects. This likely to provide a significant boost to the growth of the global drone-powered business solutions market. Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1007 The primary solutions offered by drone-powered business solutions are software and services.
Industrial Air Filtration Market 2017-2025 | Alfa Laval, Clarcor Inc., Mann + Hu …
Global Industrial Air Filtration Market: Snapshot Occupational safety norms and policies regulating the quality of indoor air in various commercial and industrial buildings have led to the evolution of industrial air filtration market. There is a growing concerns of mitigating the effects of pollutants in ambient air in order to ensure a healthful working conditions in numerous industries such as logistics and recycling. This has led to accelerating demand for industrial

All 26156 Releases


More Releases for DLBCL

Diffuse Large B-Cell Lymphoma Market - Upcoming Development 2025 | Genentech, In …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2022 Vendors, Driving …
The research report shows the continuous growth over the years in Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market with market size, growth rate, driving & trending factors, market trends, opportunities and threats. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market report provides top vendors, geographical regions, revenue, types, application, end users. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market 2018-2022 provides market landscape, market sizing, buyers, suppliers, new entrants, market share, revenue, consumption,
Diffuse Large B-Cell Lymphoma Market trends and dynamics 2017 - 2025 : Genentech …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma Market Trends and Opportunities 2017 - 2025 : Infi …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma Market is on Higher Demand 2017 - 2025
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
DLBCL receives FDA orphan drug designation for eFT508
US Food and Drug Administration has announced orphan drug designation to eFT508, a highly selective inhibitor of MNK1 and MNK2 for the treatment of diffuse large B-cell lymphoma. The drug is developed by eFFECTOR Therapeutics. The company has initiated to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of the agent in patients with B-cell hematologic malignancies. The company also is conducting a phase 1/phase 2 dose-escalation trial of eFT508